Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Caio M. Rocha Lima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0000-2450-6258; OpenAlex author ID A5033039101, A5072721608, A5111478894. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 1, last author 2)
Trials
5 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: 1 trial · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: 3 papers · 2013: 1 paper, 2 trials · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 10

  1. Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients. Co-author DOI 10.1002/jso.27365↗
  2. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer. Co-author DOI 10.21037/jgo.2019.09.12↗
  3. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2017.10.12↗
  4. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in met… Co-author PMID 30807558↗
  5. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanolipos… Co-author PMID 30807559↗
  6. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗
  7. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Last author DOI 10.1097/coc.0b013e3182436e8c↗
  8. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jvir.2012.09.012↗
  9. Emerging cell-cycle inhibitors for pancreatic cancer therapy. First author DOI 10.1517/14728214.2012.739606↗
  10. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Co-author PMID 23112883↗

Trials 5

  1. CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT01835041↗
  2. CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT01839981↗
  3. Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy Study chair NCT00691054↗
  4. Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Study chair NCT00448838↗
  5. Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer Principal investigator NCT00290693↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter J. Hosein · 5 shared papers, 2012–2019 · strength 0.28
  2. Clancy J. Clark · 1 shared paper, 2023 · strength 0.18
  3. Christopher W. Mangieri · 1 shared paper, 2023 · strength 0.18
  4. Perry Shen · 1 shared paper, 2023 · strength 0.18
  5. Sofia Palacio · 2 shared papers, 2018–2019 · strength 0.18
  6. Jessica MacIntyre · 3 shared papers, 2013–2018 · strength 0.15
  7. Jaime Rafael Merchan · 3 shared papers, 2013–2018 · strength 0.15
  8. Edward M. Wolin · 1 shared paper, 2018 · strength 0.12
  9. Tanios Bekaii‐Saab · 1 shared paper, 2018 · strength 0.12
  10. Kenneth H. Yu · 1 shared paper, 2018 · strength 0.12
  11. Govindarajan Narayanan · 2 shared papers, 2012–2015 · strength 0.07
  12. Soley Bayraktar · 1 shared paper, 2012 · strength 0.06
  13. Gilberto Lopes · 1 shared trial, 2008 · strength 0.05
  14. Moh'd M. Khushman · 1 shared paper, 2015 · strength 0.04
  15. Lorraine Portelance · 1 shared paper, 2015 · strength 0.04
  16. Ching-Wei David Tzeng · 1 shared paper, 2015 · strength 0.04
  17. Danny Sleeman · 1 shared paper, 2015 · strength 0.04
  18. Gilberto De Lima Lopes Jr. · 1 shared paper, 2013 · strength 0.03
  19. Alberto J. Montero · 1 shared paper, 2013 · strength 0.03
  20. Jose M. Yrizarry · 1 shared paper, 2012 · strength 0.03
  21. Mark M. Zalupski · 1 shared paper, 2012 · strength 0.03
  22. George P. Kim · 1 shared paper, 2012 · strength 0.03
  23. John Lindsay Marshall · 1 shared paper, 2012 · strength 0.03
  24. Philip A. Philip · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.